Management of Takayasu Arteritis - A 2026 Update - PubMed
5 hours ago
- #Treatment
- #Takayasu arteritis
- #Vasculitis
- Takayasu arteritis (TAK) is a chronic, large-vessel vasculitis primarily affecting young women.
- Distinguishing disease activity from vascular damage is challenging; PETVAS and VAMP show promise.
- Composite scores like TAIDAI integrate clinical features and FDG-PET for disease activity assessment.
- LVVID has been validated for damage assessment in TAK, with serum biomarkers of fibrosis being notable.
- Treatment typically combines glucocorticoids with DMARDs; methotrexate, mycophenolate mofetil, secukinumab, tofacitinib, and baricitinib are effective.
- TNF-alpha inhibitors and tocilizumab remain important in TAK management.
- Vascular interventions are reserved for severe vascular damage or ischemia threatening organ function.
- Advances in composite tools for disease activity and damage assessment aim to improve TAK management.
- More high-quality trials are needed to strengthen the evidence base for TAK treatments.